Jieqiong Zhang

Guizhou Magic Pharmaceutical (China) — China

Chemistry · Physical Sciences

7h-index215citations40works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Analytical chemistry methods development(7), Electrochemical Analysis and Applications(7), Heavy metals in environment(5), Food Allergy and Anaphylaxis Research(2), Adsorption and biosorption for pollutant removal(1)

Publications40 total

Supplementary Figure S3 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S3 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Data from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Figure S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
Supplementary Table S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025Open Access
HRA00129-C004, a Novel c-Met Antibody–Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles
Molecular Cancer Therapeutics·2025
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Molecular Cancer Therapeutics·2025
The Application of Checklist in Chronic Disease: A Comprehensive Bibliometric Analysis
Journal of Multidisciplinary Healthcare·2025· 1 citedOpen Access
Efficient voltammetric analysis for total inorganic arsenic detection in rice with enhanced sensitivity and selectivity
Food Chemistry X·2024· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Changyong Yang(18), Xing Sun(18), Yunan Tian(18), Cheng Liao(18), Li‐Min Wang(17), Lei Zhou(17), Zhijun Wang(17), Yuan Lin(17), Tingting Wu(17), Wei Zhang(17), Jiayi Li(17), Minghui Zhou(10), Yanxiang Wu(9), Xue Wang(8), Xi Chen(7), Xue Wang(7), Wei Tian(6), Songxue Wang(6), Songxue Wang(3), Wei Sheng(2)